Pfizer Q2 revenue $27.7B record; adj. EPS $2.04 (+92%); raises FY guidance $0.24

PFIZER INC

2022-Q2 EPS reported $3.10 revenue$53,402,000,000

Q2 revenue $27.7B (+47% YoY, +53% operational); Paxlovid contributed $8.1B, Comirnaty +20% operationally.
Reported diluted EPS $1.73 (+77%); adjusted diluted EPS $2.04 (+92%), beating expectations.
Raised FY2022 adj. EPS guidance to $6.30-6.45 (lower end up $0.05); revenue reaffirmed $98-102B.
H1 capital: $4.5B dividends, $2B share buybacks; completed $6.3B Arena acquisition; announced $13.3B Biohaven deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.